Helius Medical Tech Q1 2024 GAAP EPS $(3.08) Misses $(2.70) Estimate, Sales $135.000K Beat $130.500K Estimate
Helius Medical Tech Q1 2024 GAAP EPS $(3.08) Misses $(2.70) Estimate, Sales $135.000K Beat $130.500K Estimate
Helius Medical Tech 2024年第一季度GAAP每股收益（3.08美元）未達到預期（2.70美元），銷售額13.5萬美元超過預期的13.500萬美元
Helius Medical Tech (NASDAQ:HSDT) reported quarterly losses of $(3.08) per share which missed the analyst consensus estimate of $(2.70) by 14.07 percent. This is a 30.32 percent increase over losses of $(4.42) per share from the same period last year. The company reported quarterly sales of $135.000 thousand which beat the analyst consensus estimate of $130.500 thousand by 3.45 percent. This is a 21.62 percent increase over sales of $111.000 thousand the same period last year.
Helius Medical Tech（納斯達克股票代碼：HSDT）公佈的季度虧損爲每股3.08美元，比分析師普遍預期的2.70美元（2.70美元）低14.07％。與去年同期每股虧損4.42美元（4.42）相比，增長了30.32％。該公司公佈的季度銷售額爲13.5萬美元，比分析師普遍預期的130,500美元高出3.45％。這比去年同期的11.1萬美元的銷售額增長了21.62％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。